Karyopharm Therapeutics Inc. (KPTI) Rises A lot Today, Is Now One of The Best Performer

April 17, 2018 - By Maria Brooks

Investors sentiment decreased to 1.56 in Q4 2017. Its down 0.94, from 2.5 in 2017Q3. It is negative, as 4 investors sold Karyopharm Therapeutics Inc. shares while 21 reduced holdings. 11 funds opened positions while 28 raised stakes. 30.26 million shares or 8.41% more from 27.91 million shares in 2017Q3 were reported.
Sg Americas Secs Ltd Liability Corp accumulated 10,094 shares or 0% of the stock. Proshare Limited Liability owns 30,437 shares or 0% of their US portfolio. 3,541 are held by Citigroup. New York State Common Retirement Fund holds 0% or 30,500 shares in its portfolio. Iguana Healthcare Mgmt Ltd Liability reported 300,000 shares. Dimensional Fund Advsr Limited Partnership holds 0% or 315,890 shares in its portfolio. Millennium Mngmt Lc invested in 436,836 shares or 0.01% of the stock. Art Limited Company stated it has 0.01% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Alliancebernstein Ltd Partnership accumulated 118,430 shares or 0% of the stock. Bancshares Of New York Mellon Corporation stated it has 163,093 shares. Swiss Bancorp has 56,850 shares. Mutual Of America Mgmt Limited Liability Com reported 155,525 shares. Barclays Public Limited Company stated it has 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Metropolitan Life Insurance Ny has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Fmr Lc has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI).

Since December 11, 2017, it had 0 insider purchases, and 23 sales for $2.49 million activity. Shacham Sharon also sold $100,769 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Monday, January 8. Mirza Mansoor Raza sold 2,500 shares worth $42,525. Shares for $19,500 were sold by Primiano Christopher Brett.

The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a huge mover today! The stock increased 7.69% or $1.08 during the last trading session, reaching $15.13. About 476,560 shares traded or 12.44% up from the average. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 23.92% since April 17, 2017 and is uptrending. It has outperformed by 12.37% the S&P500.
The move comes after 6 months positive chart setup for the $751.25 million company. It was reported on Apr, 17 by Barchart.com. We have $16.49 PT which if reached, will make NASDAQ:KPTI worth $67.61M more.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Ratings Coverage

Among 6 analysts covering Karyopharm Therapeutics (NASDAQ:KPTI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Karyopharm Therapeutics had 10 analyst reports since November 2, 2017 according to SRatingsIntel. RBC Capital Markets maintained Karyopharm Therapeutics Inc. (NASDAQ:KPTI) rating on Thursday, November 2. RBC Capital Markets has “Buy” rating and $15.0 target. The rating was maintained by Jefferies on Friday, March 16 with “Buy”. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, January 11 report. The firm has “Buy” rating given on Thursday, March 15 by Robert W. Baird. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, November 15. On Tuesday, April 10 the stock rating was maintained by JP Morgan with “Overweight”. The rating was maintained by Canaccord Genuity on Monday, March 12 with “Buy”. As per Friday, March 2, the company rating was maintained by RBC Capital Markets. As per Friday, March 16, the company rating was maintained by JP Morgan. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, December 12 report.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $751.25 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-HodgkinÂ’s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.